Therapy of aggressive pituitary tumors

Treatment of pituitary neoplasms with temozolomide

(2010) Luis V. Syro et al.   CANCER

Salvage therapy with temozolomide in patients with aggressive or metastatic pituitary adenomas: experience in six cases

(2010) Marco Losa et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

SOM230 (Pasireotide) and Temozolomide Achieve Sustained Control of Tumour Progression and ACTH Secretion in Pituitary Carcinoma with Widespread Metastases

(2010) H. Bode et al.   EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES

Pasireotide (SOM230) Demonstrates Efficacy and Safety in Patients with Acromegaly: A Randomized, Multicenter, Phase II Trial

(2010) S. Petersenn et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Temozolomide Treatment for Aggressive Pituitary Tumors: Correlation of Clinical Outcome with O6-Methylguanine Methyltransferase (MGMT) Promoter Methylation and Expression

(2010) Zachary M. Bush et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Temozolomide Treatment in Aggressive Pituitary Tumors and Pituitary Carcinomas: A French Multicenter Experience

(2010) Gérald Raverot et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Atypical pituitary adenomas: incidence, clinical characteristics, and implications

(2010) Gabriel Zada et al.   JOURNAL OF NEUROSURGERY

Role of stereotactic radiosurgery in the management of pituitary adenomas

(2010) Frederic Castinetti et al.   Nature Reviews Endocrinology

Radiation treatment strategies for acromegaly

(2010) Nathan C. Rowland et al.   Neurosurgical Focus

Pasireotide Alone or with Cabergoline and Ketoconazole in Cushing's Disease

(2010) Richard A. Feelders et al.   NEW ENGLAND JOURNAL OF MEDICINE

Radiosurgery for pituitary adenomas: evaluation of its efficacy and safety

(2010) Douglas G Castro et al.   Radiation Oncology

The dopamine–somatostatin chimeric compound BIM-23A760 exerts antiproliferative and cytotoxic effects in human non-functioning pituitary tumors by activating ERK1/2 and p38 pathways

(2009) Erika Peverelli et al.   CANCER LETTERS

High incidence of low O6-methylguanine DNA methyltransferase expression in invasive macroadenomas of Cushing's disease

(2009) Akira Takeshita et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

The German ACROSTUDY: past and present

(2009) M Buchfelder et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Long-Term Results of Stereotactic Radiosurgery in Secretory Pituitary Adenomas

(2009) Frederic Castinetti et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Multimodality Treatment for Invasive Pituitary Adenomas

(2009) Mark Hornyak et al.   POSTGRADUATE MEDICINE

Low O6-methylguanine-DNA methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumours

(2008) Ann I. McCormack et al.   CLINICAL ENDOCRINOLOGY

Efficacy of a dopamine-somatostatin chimeric molecule, BIM-23A760, in the control of cell growth from primary cultures of human non-functioning pituitary adenomas: a multi-center study

(2008) T. Florio et al.   ENDOCRINE-RELATED CANCER

Treatment of Pituitary-Dependent Cushing’s Disease with the Multireceptor Ligand Somatostatin Analog Pasireotide (SOM230): A Multicenter, Phase II Trial

(2008) M. Boscaro et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Interferon-γ inhibits cellular proliferation and ACTH production in corticotroph tumor cells through a novel janus kinases–signal transducer and activator of transcription 1/nuclear factor-kappa B inhibitory signaling pathway

(2008) Marta Labeur et al.   JOURNAL OF ENDOCRINOLOGY

Management of aggressive pituitary adenomas: current treatment strategies

(2008) Michael Buchfelder   Pituitary

Pasireotide (SOM230): Development, mechanism of action and potential applications

(2007) Herbert A. Schmid   MOLECULAR AND CELLULAR ENDOCRINOLOGY